Patents by Inventor Suzanne Ostrand-Rosenberg
Suzanne Ostrand-Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10377810Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.Type: GrantFiled: April 20, 2017Date of Patent: August 13, 2019Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTYInventor: Suzanne Ostrand-Rosenberg
-
Publication number: 20180291114Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, a bispecific T-Cell engager recombinant polypeptide comprising an antibody, fragment thereof, or single chain variable fragment that binds to CD3 of a T-cell antigen receptor and an antibody, fragment thereof, or single chain variable fragment that binds to Programmed Death Ligand 1 (PDL1) on a cancerous tumor cell to counteract the immune tolerance of cancer cells.Type: ApplicationFiled: June 13, 2018Publication date: October 11, 2018Inventors: Suzanne Ostrand-Rosenberg, Darryl L. Carter
-
Publication number: 20170226181Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.Type: ApplicationFiled: April 20, 2017Publication date: August 10, 2017Inventor: SUZANNE OSTRAND-ROSENBERG
-
Patent number: 9650429Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.Type: GrantFiled: February 9, 2015Date of Patent: May 16, 2017Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTYInventor: Suzanne Ostrand-Rosenberg
-
Publication number: 20150232532Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.Type: ApplicationFiled: February 9, 2015Publication date: August 20, 2015Inventor: SUZANNE OSTRAND-ROSENBERG
-
Patent number: 8956619Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDLL and inhibits PDLL-PD1 interactions thereby overcoming PDLL-induced immune suppression and restoring T cell activation.Type: GrantFiled: October 25, 2012Date of Patent: February 17, 2015Assignee: University of Maryland, Baltimore CountyInventor: Suzanne Ostrand-Rosenberg
-
Publication number: 20130149305Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDLL and inhibits PDLL-PD1 interactions thereby overcoming PDLL-induced immune suppression and restoring T cell activation.Type: ApplicationFiled: October 25, 2012Publication date: June 13, 2013Inventor: SUZANNE OSTRAND-ROSENBERG
-
Patent number: 8444965Abstract: The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.Type: GrantFiled: September 23, 2010Date of Patent: May 21, 2013Assignee: University of Maryland, Baltimore CountyInventors: Suzanne Ostrand-Rosenberg, Jacobus J. Bosch, Bruce R. Ksander
-
Patent number: 8026224Abstract: Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating-a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor.Type: GrantFiled: December 20, 2005Date of Patent: September 27, 2011Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College, University of MarylandInventors: Suzanne Ostrand-Rosenberg, Sivasubramanina Baskar, Laurie H. Glimcher, Gordon J. Freeman, Lee M. Nadler
-
Publication number: 20110165187Abstract: The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.Type: ApplicationFiled: September 23, 2010Publication date: July 7, 2011Inventors: Suzanne Ostrand-Rosenberg, Jacobus J. Bosch, Bruce R. Ksander
-
Patent number: 7807186Abstract: The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.Type: GrantFiled: January 16, 2008Date of Patent: October 5, 2010Assignee: University of Maryland, Baltimore CountyInventors: Suzanne Ostrand-Rosenberg, Jacobus J. Bosch, Bruce R. Ksander
-
Publication number: 20100021472Abstract: Aspects of the present invention relate to molecular biology and medicine. More specifically, some embodiments include methods for treating and/or diagnosing inflammation and/or cancer using agents that inhibit the binding of a pro-inflammatory protein or protein complex (e.g., S100A8 and/or S100A9) to a carboxylated glycan expressed on a myeloid (e.g., MDSC), monocytic, dendritic, endothelial, or tumor cell.Type: ApplicationFiled: July 27, 2009Publication date: January 28, 2010Inventors: Geetha Srikrishna, Hudson H. Freeze, Suzanne Ostrand-Rosenberg, Pratima Sinha
-
Publication number: 20080206288Abstract: The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.Type: ApplicationFiled: January 16, 2008Publication date: August 28, 2008Inventors: Suzanne Ostrand-Rosenberg, Jacobus J. Bosch, Bruce R. Ksander
-
Publication number: 20060099195Abstract: Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating-a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor.Type: ApplicationFiled: December 20, 2005Publication date: May 11, 2006Applicants: Dana-Farber Cancer Institute, Inc., University of Maryland, Baltimore County, President and Fellows of Harvard CollegeInventors: Suzanne Ostrand-Rosenberg, Sivasubramanian Baskar, Laurie Glimcher, Gordon Freeman, Lee Nadler
-
Publication number: 20030124103Abstract: Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor.Type: ApplicationFiled: September 30, 2002Publication date: July 3, 2003Inventors: Suzanne Ostrand-Rosenberg, Sivasubramanian Baskar, Laurie H. Glimcher, Gordon J. Freeman, Lee M. Nadler
-
Publication number: 20020086421Abstract: TUMOR CELLS WITH INCREASED IMMUNOGENICITY AND USES THEREFOR Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor.Type: ApplicationFiled: September 27, 2001Publication date: July 4, 2002Applicant: University of MarylandInventors: Suzanne Ostrand-Rosenberg, Sivasubramanian Baskar, Laurie H. Glimcher, Gordon J. Freeman, Lee M. Nadler
-
Patent number: 6319709Abstract: Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor.Type: GrantFiled: November 29, 1999Date of Patent: November 20, 2001Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, University of Maryland, Baltimore CountyInventors: Suzanne Ostrand-Rosenberg, Sivasubramanian Baskar, Laurie H. Glimcher, Gordon J. Freeman, Lee M. Nadler
-
Patent number: 6149905Abstract: Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4.sup.Type: GrantFiled: September 23, 1998Date of Patent: November 21, 2000Assignees: Genetics Institute, Inc., Dana-Farber Cancer Institute, Presidents and Fellows of Harvard CollegeInventors: Suzanne Ostrand-Rosenberg, Sivasubramanian Baskar, Laurie H. Glimcher, Gordon J. Freeman, Lee M. Nadler
-
Patent number: 5858776Abstract: Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4.sup.Type: GrantFiled: November 3, 1993Date of Patent: January 12, 1999Assignees: Repligen Corporation, Dana-Farber Cancer Institute, President and Fellows of Harvard CollegeInventors: Suzanne Ostrand-Rosenberg, Sivasubramanian Baskar, Laurie H. Glimcher, Gordon J. Freeman, Lee M. Nadler